NHIC, Daewon poles apart on medicine negotiation

Published: 2008-07-31 06:58:00

Updated: 2008-07-31 06:58:00

The National Health Insurance Corporation and Daewon Pharm remain far apart in their negotiations over the price evaluation of home-grown Peluvi tablets (felubiprofen), new NSAID (nonsteroidal anti-inflammatory drug) for treatment of osteoarthritis.

Daewon is calling for a more “profitable'' p...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK